Durastab Medtech Co., Ltd. has always adhered to the mission of "making diagnostic reagents more stable and more accurate" since its establishment, and is committed to providing excellent ready-to-use reagent solutions to global advanced medical diagnostic companies.
To date, Durastab has successfully provided products to over 600 companies and research teams at thousands of universities and scientific research institutions worldwide, among which are more than 50 listed IVD companies.
About Us
Search
Search
Durastab's Blocker reagents are widely applicable in the R&D and industrial production of IVD kits. Customers can evaluate corresponding reagent series based on their specific assay systems to screen for the most effective component. The products are suitable for use in most IVD projects employing sandwich antigen detection, competitive, or IgM capture methods, such as in Cardiac Markers, Tumor Markers, Inflammatory Markers, Infectious Diseases, Thyroid Function, and Renal Function testing.
Blocker
Durastab's Blocker reagents effectively reduce false-positive or false-negative results caused by interferents in immunoassays. In immunoassay experiments, test results are susceptible to interference from endogenous antibodies or other immunoglobulin-binding substances present in samples. These interferents are collectively known as immunoassay interferents, and assay formats particularly vulnerable to interference primarily include sandwich, competitive, and IgM capture assays. Currently known major interferents include Heterophile Antibodies (HA), Rheumatoid Factors (RF), and Human Anti-Animal Antibodies (HAAA), among others.
Durastab's Blocker reagents are widely applicable in the R&D and industrial production of IVD kits. Customers can evaluate corresponding reagent series based on their specific assay systems to screen for the most effective component. The products are suitable for use in most IVD projects employing sandwich antigen detection, competitive, or IgM capture methods, such as in Cardiac Markers, Tumor Markers, Inflammatory Markers, Infectious Diseases, Thyroid Function, and Renal Function testing.
Active Blockers: This category of reagents exhibits high affinity for interfering antibodies. By actively binding to the interfering antibodies, they employ steric hindrance to block the interaction between the interfering antibodies and the detection or capture antibodies.
Passive Blockers: Typically consisting of animal serum or IgG, these reagents are added at high concentrations. They function by providing an excess of alternative binding sites, causing the interfering antibodies to preferentially bind to the blocker instead of the detection or capture antibodies, thereby reducing interference.
| Art no. | Type | Reaction System | Methodology | Application | Instructions |
|---|---|---|---|---|---|
| HBR-001 | Active & Passive | Mouse | Immunoassay | CLIA/ ELISA: Enzyme Conjugate: @ 5-100 μg/mL LFIA: Sample pad treatment: @ 0.2-0.4 mg/mL | |
| HBR-007 | Active & Passive | Mouse | Immunoassay | ||
| HBR-035 | Active & Passive | Mouse | CLIA, LFIA | CLIA: Enzyme Conjugate: @ 5-100 μg/mL LFIA: Sample pad treatment: @ 0.2-0.4 mg/mL | |
| HBR-041 | Active & Passive | Mouse | CLIA, LFIA | ||
| HBR-045 | Active & Passive | Mouse | CLIA, LFIA | ||
| HBR-064 | Active & Passive | Mouse | CLIA, LFIA | ||
| HBR-072 | Active & Passive | Mouse | CLIA, LFIA | ||
| HBR-157 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | CLIA: Enzyme Conjugate: @ 5-100 μg/mL LFIA: Sample pad treatment: @ 0.2-0.4 mg/mL Clinical chemistry: R1 reagent: @ 0.5-1.0 % (v/v) | |
| HBR-162 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-194 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-208 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-238 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-253 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-316 | Active & Passive | Mouse, Goat | CLIA, LFIA, Clinical chemistry | ||
| HBR-339 | Active & Passive | Mouse, Rabbit | CLIA, LFIA, Clinical chemistry | ||
| HBR-361 | Active & Passive | Mouse, Goat, Rabbi | CLIA, LFIA, Clinical chemistry | ||
| HBR-400 | Passive | Mouse | CLIA | CLIA: Enzyme Conjugate: @ 5-100 μg/mL | |
| HBR-401 | Passive | Mouse | CLIA | ||
| HBR-402 | Active & Passive | Mouse | Immunoassay | CLIA: Enzyme Conjugate: @ 5-100 μg/mL LFIA: Sample pad treatment: @ 0.2-0.4 mg/mL | |
| HBR-403 | Active & Passive | Mouse | Immunoassay |
For research use only or for further use in the production of detection kits. Not for human or animal use!
Q1: How do I choose a blocking buffer for ELISA?
A: Start from the assay matrix: BSA-based (BSAB) for standard systems, casein-based (CABS, 5%/10% concentrates) for strong background reduction on nitrocellulose and plates, Ultra for demanding low-background assays, and protein-free (PFBS, PFBK) when foreign proteins must be excluded.
Q2: What is the difference between active and passive blockers?
A: Passive blockers occupy free binding sites on the solid phase, while active blockers specifically neutralize interfering antibodies such as HAMA, rheumatoid factor and heterophilic antibodies in patient samples.
Q3: What is the difference between GelatiNSBlock-P and GelatiNSBlock-F?
A: They are gelatin-based blockers from different source materials (P and F), offering different background profiles; screen both if standard BSA/casein blockers leave residual non-specific signal.
Q4: How are the 5× and 10× casein blockers used?
A: Dilute the concentrate with your assay buffer to 1× before use; the concentrated format reduces shipping and storage volume for kit manufacturing.
Q5: Can blockers be used in Western blotting as well as ELISA?
A: Yes - casein and gelatin-based blockers are widely used on nitrocellulose and PVDF membranes, while the ELISA-focused blockers address microplate surfaces.
Committed to providing excellent ready-to-use reagent solutions to global advanced medical diagnostic companies.
Send RequestDurastab Medtech (Durastab IVD) is an IVD raw materials manufacturer based in Shenzhen, China, supplying ELISA and CLIA substrates, enzyme stabilizers, blocking buffers and reagent preservatives to in vitro diagnostic manufacturers worldwide.
By submitting this form,you consent to receive marketing updates from Durastab Medtech (Durastab IVD) .